Suspension cells were maintained in RPMI-1640 supplemented with 10% FCS plus antibiotics, adherent cells were grown in DMEM plus 10% FCS and antibiotics, while endothelial cells were cultures in endothelial cell medium with growth factors (Promo Cell) and antibiotics.
Apoptosis induction and assessment
Apoptosis was induced by addition of 50 µM (final concentration) of α-TOS dissolved in DMSO, controls were treated with DMSO only. For suspension cells, cell density was 0.5 × 10 6 per ml at the onset of treatment, malignant adhesion cells were treated when 70-80% confluent, while normal adhesion cells were left to grow to confluency before treatment.
Apoptosis was assessed in suspension cells by the annexin V-FITC method as described earlier (Neuzil et al, 1999) and in adherent cells by the TUNEL-FITC method according to the manufacturer's protocol (Boehringer, Germany). The percentage of annexin V-positive cells was determined by flow cytometry (Becton Dickinson) and that of TUNEL-FITC-positive cells by scoring at least 100 cells in a fluorescent microscope.
RESULTS AND DISCUSSION
We studied the effect α-TOS in a wide range of cell lines and normal cells. Strikingly, all cell lines tested were susceptible to α-TOS, as treatment with a pharmacological dose of 50 µM for 12 h triggered apoptosis in 28-65% of the cells (Table 1 ). In general, leukaemic cell lines, including monocytic and macrophage cell lines, B and T lymphoma cells, were more sensitive towards α-TOS than adherent carcinoma cell lines. Notwithstanding, α-TOS was pro-apoptotic towards lung, breast and colorectal cancer cells. Moreover, α-TOS efficiently killed p53-and p 21 Waf 1 /Cip 1 -deficient mutants of the HCT-116 colon cancer cell line (not shown). Since mutations of tumour suppression genes are frequent complications in cancer chemo-and radiotherapy, this highlights the potential of α-TOS as an anticancer agent (Kaelin, 1999) .
In contrast, normal cell types, including haematopoietic cells, fibroblasts, endothelial cells, cardiomyocytes, hepatocytes and smooth muscle cells, showed no susceptibility to apoptosis induced by α-TOS. This can be exemplified by cardiomyocytes where the effects of pro-apoptotic stimuli on morphology, cytoskeleton and beating rate were compared. While α-TOS had no effect, adriamycin induced morphological and cytoskeletal changes and
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Selective cancer cell killing by α-tocopheryl succinate decreased beating rate (not shown). These findings are complemented by reports which showed no toxic effect of α-TOS on normal fibroblasts (Jha et al, 1999) or prostate cells (Israel et al, 2000) , and by a finding that α-TOS was toxic towards malignant but protective for normal stem cells (Fariss et al, 1994) .
The reasons for the selectivity of α-TOS are not known at present. However, the fact that it appears to affect rapidly proliferating cells is suggestive of a role of the cell cycle in sensitivity of malignant cells to the vitamin E analogue. We have found that pro-apoptotic activity of α-TOS positively correlated with its inhibitory activity on protein kinase C (PKC) (Neuzil et al, 2001) , and PKC activity has been associated with a more proliferative and invasive phenotype of malignant cells, as shown e.g. for breast (Ways et al, 1995) or renal carcinoma cells (Engers et al, 2000) . Moreover, PKC is also involved in fast transition through the cell cycle by regulating the cell cycle checkpoint proteins p
21 Waf 1 /Cip 1 and p27 Kipl (Frey et al, 1997) , and α-TOS has been shown to decrease levels of the cdk2-cyclin A complex and increased p 21 Waf 1 /Cip 1 in a human breast cancer cell line (Turley et al, 1997) . Similarly, treatment of colon cancer cells with Trolox, a watersoluble analogue of vitamin E, led to the expression of p 21 Waf 1 /Cip 1 and sensitization of the cells towards 5-fluorouracil (Chinery et al, 1997) . Notably, we have found that normal adherent cells which were confluent and thus contact-arrested and quiescent were resistant to α-TOS-induced toxicity (not shown). Bronchocarcinoma cell line BEAS-2B 1.9 ± 1.1 36.2 ± 5.9
Colon carcinoma cell lines CaCo-2 6.5 ± 2.2 63.1 ± 9.8 HCT-116 7.5 ± 1.1 37.3 ± 4.8 HCT-15 3.5 ± 1.6 32.3 ± 4.5 DKO-1 6.5 ± 3.1 45.2 ± 6.3 DKO-3 6.1 ± 4.5 43.2 ± 7.1 DKS-5 5.5 ± 3.1 41.2 ± 6.4 DKS-8 7.2 ± 1.9 37.2 ± 5.8 DLD-1 5.2 ± 1.8 32.3 ± 5.3 LS1034 4.2 ± 2.6 35.9 ± 6.9
Normal cells
Mouse peritoneal macrophages 2.1 ± 1.1 5.5 ± 3.4 Human peripheral monocytic cells 3.5 ± 2.8 6.2 ± 4.1 Human monocyte-derived macrophages 2.9 ± 1.5 5.2 ± 1.5 Human skin fibroblasts b 3.5 ± 0.9 6.1 ± 2.5 Human foreskin fibroblasts 3.8 ± 3.2 6.5 ± 4.7 Human umbilical vein endothelial cells 3.1 ± 1.2 6.5 ± 4.2 Rat intestinal epithelial cells 1.8 ± 1.6 3.5 ± 4.8 Rat neonatal cardiomyocytes 1.1 ± 0.9 4.2 ± 3.1 Rat neonatal hepatocytes 2.5 ± 1.9 4.3 ± 3.2 Rat smooth muscle cells 2.5 ± 1.8 4.9 ± 3.2 a Apoptosis was assessed following 12-h exposure of the cells to 50 µM α-TOS. For adherent cells, the extent of apoptosis is expressed as a sum of the corresponding values for cells that remained attached and those that detached during the experiment. Apoptosis extent was assessed by the annexin V method for suspension cells and TUNEL staining for adherent cells, and is expressed in % apoptotic cells as mean ± SD (n = 3-6).
b
Normal proliferating adherent cells were left to reach confluence before treatment
In conclusion, our results strongly suggest that α-TOS, a pharmacologically relevant micronutrient without known side-effects (Bendich and Machlin, 1988) , is a potent pro-apoptotic agent for a variety of malignant cells, while being non-toxic for normal cells, and warrants testing as an anticancer drug or adjuvant in experimental animal models of tumorigenesis and leukaemia. This notion is further encouraged by recent findings that α-TOS inhibited tumour growth in nude mice with colon-cancer xenografts, similarly or more potently than did other experimental or established anticancer agents (Neuzil et al, 2001; Chinery et al, 1997) . Furthermore, free vitamin E or α-tocopheryl acetate, the usual pharmacological form of vitamin E, do not have pro-apoptotic activity (Quian et al, 1997; Neuzil et al, 1999) . Hence, our results may have important implications for therapy and prevention of cancer.
